LivingGLP1
Study S001628

LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES

Registration

Registration
NCT01753362
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
84
Start
2012-12
Primary completion
2017-12
Lead sponsor
University at Buffalo
Conditions
Type 1 Diabetes
Interventions
DRUG:liraglutide; DRUG:placebo
Results posted
TRUE

Registered primary outcomes

  • HbA1c [26 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.